Agilent Technologies Introduces Next-Generation Sequencing Cancer Research Panels
SANTA CLARA, California--Agilent Technologies Inc. today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
Designed in collaboration with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University, ClearSeq AML provides comprehensive coverage of mutations and enables swift progression of sample processing to analysis in less than 48 hours. The AML gene panel will be followed by the release of additional ClearSeq panels for cancer research throughout the coming months.
“We are pleased to introduce the ClearSeq family of products, a comprehensive set of targeted NGS gene panels for cancer research,” said Jacob Thaysen, vice president and general manager of Agilent’s Diagnostics and Genomics Group. “ClearSeq NGS panels are expert-identified products that will provide customers with a complete end-to-end anatomical-to-molecular genomics portfolio that includes solutions ranging from IHC for cancer diagnosis to NGS for cancer research.”
Acute myeloid leukemia (AML) is the most common myeloid neoplasm affecting adults, and the role of chromosomal structural variations in its molecular pathogenesis is well documented. In recent years, next-generation sequencing has led to a revolution in the study of hematological malignancies and shown that insertions, deletions (indels), and mutations play an essential part in the pathogenesis of AML. Genetic information, coupled with standard anatomical findings, has provided a deeper characterization and classification of AML.
ClearSeq AML provides 99.9 percent design coverage of targeted coding exons. Agilent’s high-performance cancer panels enable the study of more complex genomic alterations in cancer, and deliver quick and accurate identification of relevant information. ClearSeq panels are based on SureSelect and HaloPlex technology, offering superior sensitivity and accuracy compared with other hybridization or PCR-based methods, thus minimizing the risk of false-positive results. ClearSeq panels can be easily incorporated into routine laboratory workflows. Sequence data analysis and mutation reporting can be completed in three simple steps using Agilent’s SureCall software.
To learn more about how to incorporate this powerful set of panels into your research protocol, visit www.agilent.com/genomics/ClearSeqAML.